Metabolic Disorders in Heart Failure and Cancer
View Full Paper
Ask AI
Bookmark
Share
Key result
Metabolic disorders such as cachexia and sarcopenia frequently complicate heart failure and cancer, increasing morbidity and mortality while lacking established guideline-recommended therapies.
Why the study?
Heart failure and cancer frequently co-occur with metabolic disorders causing muscle wasting, yet few therapeutic options exist and guideline-recommended therapies for cachexia are lacking.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports screening for cachexia and sarcopenia in HF and cancer; leaves open targeted therapies for prospective trials.
Structured PICO
P
Population
Patients with heart failure and cancer suffering from metabolic disorders such as sarcopenia and cachexia
Sarcopenia and cachexia are critical, overlapping complications in both heart failure and cancer that significantly worsen prognosis and urgently require the development of targeted therapeutic strategies.
Limitations
- Very few therapeutic options have been established to treat these co-morbidities.
- There is currently no guideline recommended therapy for the treatment of cachexia.
Cite This Study
Lena et al. (2018) conducted a review in Heart failure and cancer (cachexia and sarcopenia). Metabolic disorders such as cachexia and sarcopenia frequently complicate heart failure and cancer, increasing morbidity and mortality while lacking established guideline-recommended therapies.
Topics
View Full Paper
Ask AI
Bookmark
Share